Methods: e-MISAGO enrolled more than 3000 patients treated with the Misago stent in 94 European centers. All clinical data collected through an EDC platform are fully monitored and all reported serious adverse events are independently adjudicated. Primary safety (at 30 days) and efficacy endpoint (at 1 year) match the VIVA criteria. Results: Patients (68% male) were 67Ϯ10 years old, 63% were smokers, 36% had diabetes mellitus (36% IDDM), 46% had hypercholesterolemia and 76% arterial hypertension. Patients had history of previous coronary artery disease in 32% of the cases and 14% previous myocardial infarction. Claudication and symptomatic ischemia concerned 99% and 96% of the patient population. Mean lesion length was 64.5Ϯ59.0 mm, with reference vessel diameter 6.3Ϯ1.3 mm. Mean lesions' stenosis was 88.6Ϯ12.4% and 43.3% of the lesions were totally occluded. On average 1.2Ϯ0.5 vessels per patient were treated with 1.2Ϯ0.45 stents per lesion. At baseline mean ABI was 0.59Ϯ0.22 and mean Rutherford score was 2.51Ϯ1.31. At 12 months ABI improved in 81% patients and the mean increased to 0.85Ϯ0.24; Rutherford score improved in 76% patients with mean value of 0.72Ϯ1.16. The overall composite adverse events rate of death, amputation, and revascularization was 9.7%. Conclusions: The interim results from the e-MISAGO registry indicate promising device performance of the Misago RX nitinol stent at 1 year.
Background:
The impact of vascular injury on drug transfer and vessel healing following Paclitaxel Coated Balloon (PCB) use has not been described. We hypothesized that the vessel uptake of paclitaxel and its resulting effect on healing is highly influenced by the degree of mechanical injury exerted to the vessel wall following balloon inflation. Methods: A total of 19 PCB (Cotavance, Medrad, Inc. Indianola, PA) were inflated in the iliofemoral territory of 8 domestic swine targeting a 1.2:1 balloon to artery ratio (BAR). All arteries were harvested at either 14 (nϭ9) or 30 (nϭ10) days for the evaluation of tissue paclitaxel levels and histology. Based on the histological injury scores, all vessel segments were classified into IEL ruptured (IEL-R) or IEL non-ruptured (IEL-NR). Results: A total of 19 iliofemoral arteries were included in the analysis. The IEL-R group had a higher BAR (1.44Ϯ0.08) compared to the IEL-NR (1.34Ϯ0.11, pϭ0.1). At 14 days, the median concentration of paclitaxel in the IEL-R group (1,251g/g) was higher than in the IEL-NR group (465 g/g, pϭ0.13). However, the% area of stenosis was comparable among both groups at 14 and 30 days (see table) . At 30 days, Paclitaxel tissue levels were comparable among both groups. Fibrin and inflammatory scores were consistently higher in the IEL-R group compared to the IEL-NR group at both 14 and 30 days (see table) . Conclusions: The degree of mechanical injury induced by balloon dilatation seems to influence short-term drug transfer and long-term vessel healing following PCB use. The implications of these findings on clinical outcomes deserve further evaluation in the human setting. 6, see figure) . At follow up, POBA demonstrated a progression in neointimal proliferation at distal (26.9% increase, pϽ0.001) and proximal (8.0% increase, pϭ0.05) vessel reference segments. Conversely, PCB exhibited neointimal regression in the distal (-7.7%, pϭ0.05) and proximal (1.4%, pϭ0.5) reference segments.
Conclusions:
In vivo OCT analysis showed a homogeneous inhibition of neointimal formation following paclitaxel delivery. In addition the use of PCB reduces neointimal proliferation at the borders of the stent.
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Background: Drug-coated balloons (DCB) have emerged as a potential alternative in treating PAD. This study aimed to evaluate the tissue concentrations and efficacy of using the Freeway DCB in porcine peripheral arteries. Thus no further extrapolation from coronary preclinical experiments is needed. Methods: Measurements of tissue paclitaxel concentration at 1h, 1 day, 3 days and 9 days after dilation of peripheral arteries with Freeway™ balloon (Paclitaxel-eluting DEB) for 1 or 2 min in a total of 92 porcine arteries. Inflation time dependent determination of the paclitaxcel concentration in the blood plasma Inflation time dependent determination of the remnant paclitaxel concentration on the inflated balloon Histological investigations in a porcine post-overstretch injury (1 
